Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CFO Benjamin Hohl sold 4,250 shares of the firm’s stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $22.57, for a total value of $95,922.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Benjamin Hohl also recently made the following trade(s):
- On Tuesday, May 28th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $23.18, for a total value of $98,515.00.
- On Friday, May 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.50, for a total value of $22,500.00.
- On Monday, April 29th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $16.97, for a total value of $55,152.50.
- On Thursday, April 11th, Benjamin Hohl sold 14,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.72, for a total value of $346,080.00.
Enliven Therapeutics Trading Down 2.9 %
ELVN stock opened at $22.70 on Tuesday. The business’s 50-day moving average price is $21.77 and its two-hundred day moving average price is $17.88. The firm has a market cap of $1.07 billion, a PE ratio of -11.76 and a beta of 1.11. Enliven Therapeutics, Inc. has a 1-year low of $9.80 and a 1-year high of $26.00.
Analyst Upgrades and Downgrades
Several research firms have recently commented on ELVN. Baird R W raised Enliven Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Mizuho initiated coverage on Enliven Therapeutics in a research report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 price target on the stock. Finally, Robert W. Baird initiated coverage on Enliven Therapeutics in a research report on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 price target on the stock.
Get Our Latest Research Report on Enliven Therapeutics
Institutional Trading of Enliven Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the company. AJOVista LLC acquired a new stake in shares of Enliven Therapeutics in the 4th quarter valued at about $28,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Enliven Therapeutics in the 4th quarter valued at about $66,000. Exchange Traded Concepts LLC increased its position in shares of Enliven Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock valued at $121,000 after acquiring an additional 2,208 shares during the last quarter. EntryPoint Capital LLC acquired a new stake in shares of Enliven Therapeutics in the first quarter valued at about $167,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Enliven Therapeutics by 9.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock valued at $170,000 after acquiring an additional 1,029 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.
Enliven Therapeutics Company Profile
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
See Also
- Five stocks we like better than Enliven Therapeutics
- Why is the Ex-Dividend Date Significant to Investors?
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- What Are Growth Stocks and Investing in Them
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.